PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics. Under current news, you will find a dynamic list of stories for the last thirty (30) days. You will find older news stories in our archives. Stories about specific treatments can also be found in the medical section.
If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added. Send news: contact/info+phcentral+org.
- April 22, 2014
- Persistent Pulmonary Hypertension in the Newborn Found To Be Tied To SSRI Anti-Depressants In New Study
(Pulmonary Hypertension News)
It's good to see that progress continues to be made in identifying root causes of various flavours of PH
A group of researchers ... performed a total of 7 meta-analyses based on available data resources, determining the effects of the maternal anti-depressant Selective Serotonin Reuptake Inhibitor (SSRI) on pregnancy and child health. She and her research team concluded that usage of SSRIs during the third trimester of pregnancy led to a low but significant risk of Persistent Pulmonary Hypertension in the Newborn (PPHN). It is to be noted that no such relationship was found during the early stages of pregnancy.
- April 21, 2014
- 'Usual' Sodium Intake Seems to Hit Right Balance
A new analysis suggested that most people around the world are consuming just the right amount of sodium, although the American Heart Association questioned the findings.
Salt <--> Blood pressure seems to continue to be controversial.
- April 20, 2014
- Aspirin Tied to Fewer Deaths in COPD Flares
High platelet counts in chronic obstructive pulmonary disease (COPD) exacerbations were linked to elevated mortality, which being on an antiplatelet drug appeared to counteract, an observational study showed.
- Treat-to-Target the New Goal in Lupus
An international task force has taken the first steps toward formulating a "treat to target" approach for the treatment of systemic lupus erythematosus (SLE), focusing on remission, damage prevention, and quality of life.
- Obstructive Sleep Apnea May Increase Osteoporosis Risk
Patients with obstructive sleep apnea (OSA) are more than twice as likely to develop osteoporosis as patients without OSA, even when adjusting for age, comorbid conditions, income, and geographic location, according to a population-based study in Taiwan. Results of this longitudinal study were published online April 15 in the Journal of Clinical Endocrinology and Metabolism.
- April 19, 2014
- NSAIDs Double Bleeding Risk With Anticoagulants for DVT/PE
Patients receiving an anticoagulant for deep vein thrombosis (DVT) or pulmonary embolism (PE) who take a nonsteroidal anti-inflammatory drug (NSAID) or aspirin for pain or headache, even for a few days, are at heightened risk for a major bleed, according to a new study published online April 14, 2014 in JAMA Internal Medicine.
- High-Risk Adults Often Do Not Seek Early Treatment for Flu Symptoms
Adults with underlying health conditions are more likely to report influenza-like illnesses (ILIs), but most do not seek care promptly and may be missing the chance to benefit from early antiviral treatment, researchers have found. The study results were published online April 13 in the Journal of Infectious Diseases.
- April 18, 2014
- Nocturnal oxygen improves 6min-walk by 25m vs. placebo in PAH patients with SDB
(European Heart Journal)
Noctual oxygen treatment of sleep disordered breathing in PAH patients increased 6min-walking distance by 25m compared to placebo, a study show. Sleep disordered breathing is pretty common in patients with PAH, even in those with good saturation values at daytime. (about 50% of IPAH patients suffer of SDB.)
- PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension
PK10453, an inhaled nonselective PDGFR inhibitor, PK10453, was effective in both the MCT and MCT+PN rat models of PAH. Treatment with PK10453 was associated with a significant reduction in PA pressures in ambulatory animals, an improvement in RV function, and a reduction in RV hypertrophy. Histologic analysis demonstrated an improvement in the pulmonary arteriole L/M in animals treated with PK10453 and a decrease in the phosphorylation state of AKT(Ser473), STAT3, and ERK1. There was no significant effect of PK10453 on systemic BP and no adverse effect of PK10453 on lung function. In contrast to imatinib, PK10453 is not selective for PDGFRα but rather is highly potent against both the PDGFRα and PDGFRβ isoforms. Because the PDGFRβ pathway is more highly activated than the PDGFRα in plexiform lesions of PAH, a nonselective PDGFR inhibitor such as PK10453 may have advantages in the treatment of PAH. PK10453, when administered by inhalation, has potential as a treatment for PAH
- April 17, 2014
- Japanese Pulmonary Arterial Hypertension Patients Fare Better On PAH Drugs, according to Study
(Pulmonary Hypertension News)
Fifty-six patients at the National Hospital Organization Okayama Medical Center, diagnosed between 1998 and 2012, were selected as participants. The average age of diagnosis was 32 years, with a survival rate of 96% of the patients 5 years after diagnosis, and a 78% survival rate 10 years after diagnosis. The mean survival period from the time of diagnosis while undergoing PAH treatment was 14.9 years.
Among these treated patients, 93% received prostacyclin analogs, 68% endothelia receptor antagonists, and 52% phosphodiesterase type 5 inhibitors. Overall, 75% of the patients were treated with some form of combination therapy...
- Actelion Beats First-Quarter Earnings Expectations
(The Wallstreet Journal)
Actelion presents 2nd quarter results..
- April 16, 2014
- Chinese Herb Proves Effective in Rheumatoid Arthritis (RA)
A plant extract used in traditional Chinese medicine was as effective as methotrexate for the short-term treatment of rheumatoid arthritis and was superior when the two agents were given in combination, an open-label randomized trial showed.
At 6 months, 46.4% of patients receiving methotrexate had improved by at least 50% on the American College of Rheumatology (ACR50) criteria, as had 55.1% of those receiving extracts Tripterygium wilfordii Hook F (TwHF) and 76.8% of those given both, according to Xuan Zhang, MD, of the Chinese Academy of Medical Sciences in Beijing, and colleagues...
- April 15, 2014
- Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Survival of patients with SSc-PH-ILD has modestly improved relative to historical series. While these findings may not be generalizable, improved survival may partly be due to aggressive PAH-targeted therapy
- Use of inhaled iloprost in children with pulmonary hypertension.
- Bayer Launches Educational Website For CTEPH
Bayer announced that it has launched a new educational online resource for chronic thromboembolic pulmonary hypertension (CTEPH). The educational website www.CTEPH.com is primarily aimed at healthcare professionals working with the disease..
- The homozygous VHLD126N missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension.
Von Hippel-Lindau (VHL) protein is the principal negative regulator of hypoxia sensing mediated by transcription factors. Mutations in exon 3 of the VHL gene lead to Chuvash (VHLR200W ) and Croatian (VHLH191D ) polycythemias. Here, we describe an infant of Bangladesh ethnicity with a novel homozygous VHLD126N mutation with congenital polycythemia and dramatically elevated erythropoietin (EPO) levels, who developed severe fatal pulmonary hypertension. In contrast to Chuvash polycythemia, erythroid progenitors (BFU-Es) did not reveal a marked EPO hypersensitivity. Further, NF-E2 and RUNX1 transcripts that correlate with BFU-Es EPO hypersensitivity in polycythemic mutations were not elevated. Pediatr Blood Cancer © 2014 Wiley Periodicals, Inc.
- April 14, 2014
- Astronaut hearts shift in microgravity
According to recent findings, astronauts experiencing lengthy stays outside Earth’s gravity experience a change of heart—a shape shift to be exact...
- Small Company develops therapeutic DNA for PAH
Synthetic Biologics, Inc., formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic deoxyribonucleic acid (DNA)-based therapeutics and disease-modifying medicines for serious illnesses. Its initial synthetic biologic product candidate is intended to treat pulmonary arterial hypertension (PAH) by delivering therapeutic DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill.
- April 13, 2014
- Stem Cells Seen as Promising in Lupus
Mesenchymal stem cell transplantation is showing promise as a treatment for refractory systemic lupus erythematosus, researchers have reported.
- Focus on Chronic Illness Drugs Needed
The FDA needs to re-examine the way it reviews novel drugs that treat chronic conditions to get them to market faster, the head of the agency said Thursday -- repeating a line that those in the drug development world have heard before.
- April 12, 2014
- What the Tamiflu saga tells us about drug trials and big pharma
We now know the government's Tamiflu stockpile wouldn't have done us much good in the event of a flu epidemic. But the secrecy surrounding clinical trials means there's a lot we don't know about other medicines we take.
- Docosatetraenoyl LPA is Elevated in Exhaled Breath Condensate in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective medical therapies. Recent research has focused on identifying the biological processes essential to the development and progression of fibrosis, and on the mediators driving these processes. Lysophosphatidic acid (LPA), a biologically active lysophospholipid, is one such mediator. LPA has been found to be elevated in bronchoalveolar lavage (BAL) fluid of IPF patients, and through interaction with its cell surface receptors, it has been shown to drive multiple biological processes implicated in the development of IPF. Accordingly, the first clinical trial of an LPA receptor antagonist in IPF has recently been initiated. In addition to being a therapeutic target, LPA also has potential to be a biomarker for IPF. There is increasing interest in exhaled breath condensate (EBC) analysis as a non-invasive method for biomarker detection in lung diseases, but to what extent LPA is present in EBC is not known.
- April 11, 2014
- Study Suggests Link Between Viagra And Melanoma
In recent years researchers have uncovered a potentially important pathway whereby PDE5A inhibitors (which include sildenafil– Viagra– and other drugs used to treat erectile dysfunction and pulmonary hypertension) could potentially increase the risk of developing melanoma. Now a new study provides early evidence showing an association between sildenafil and melanoma, though, like all observational studies, it is unable to demonstrate a cause-and-effect relationship.
- April 10, 2014
- Prime Time: When Docs Require Cash on Delivery
When a team of medical "mystery shoppers" tried to get primary care office visits as new patients, they discovered that they needed private insurance coverage or had to be willing to pay at least $75 in cash upfront -- or the majority of providers wouldn't see them.
- Triple therapy shows promise for severe PAH
Results of a small pilot study among patients with severe pulmonary arterial hypertension (PAH) support the long-term benefits of upfront triple combination therapy, French researchers report.
- April 9, 2014
- ICU Survivors Prone to Some Depression Symptoms
Symptoms of depression, dominated by physical manifestations such as appetite loss, fatigue, and insomnia, were found in one-third of ICU survivors followed for a year after discharge, researchers said.
- April 8, 2014
- Pre-Capillary Pulmonary Hypertension Common in Severe Heart Failure
(Medical News Net)
Pulmonary hypertension (PH) is common in patients with heart failure (HF) and is likely to include a pre-capillary component, research suggests.
- April 7, 2014
- Use of age-adjusted D-dimer levels to exclude lung blood clots
Using a patient's age to raise the threshold for an abnormal result of a blood test used to assess patients with a suspected pulmonary embolism (blood clot in lungs) appeared to be safe and led to fewer healthy patients with the diagnosis, according to a study. "Future studies should assess the utility of the age-adjusted cutoff in clinical practice. Whether the age-adjusted cutoff can result in improved cost-effectiveness or quality of care remains to be demonstrated," the authors conclude.
- Relaxed blood pressure guidelines cut millions from needing medication
New guidelines that ease the recommended blood pressure could result in 5.8 million U.S. adults no longer needing hypertension medication, according to an analysis. The findings are the first peer-reviewed analysis to quantify the impact of guidelines' change to relax the blood pressure goal in adults 60 years and older to 150/90, instead of the previous goal of ...
- April 6, 2014
- Pulmonary Hypertension in Systemic Lupus Erythematosus
Pulmonary hypertension (PH) is a life-threatening complication of systemic lupus erythematosus (SLE). Pulmonary hypertension in SLE has a variety of causes. Diagnosing early and defining the cause of PH accurately can provide better clinical outcome in SLE. We investigated the causes and characteristics of PH in patients with SLE.
- Developments in COPD
Chronic obstructive pulmonary disease (COPD) is still widely present, underdiagnosed, and undertreated throughout the world. A recent review summarizes developments that can either be applied to current diagnostic and therapeutic practices or that very shortly will be applicable.
- April 5, 2014
- Stem cell scientist guilty of falsifying data
Haruko Obokata, a stem cell scientist at the RIKEN Center for Development Biology in Kobe, Japan, has been found guilty of misconduct by a committee of investigators led by her own government-funded institute after other researchers questioned the findings.
- Implementing Lessons Learned From Previous Bronchial Biopsy Trials in a New Randomized Controlled COPD Biopsy Trial With Roflumilast
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease mediated by an array of inflammatory cells and mediators, but above all, CD8+ T-lymphocytes, macrophages and neutrophils are important players in disease pathogenesis. Roflumilast, a first-in-class, potent and selective phosphodiesterase 4 (PDE4) inhibitor, reduces the rate of exacerbations in patients with a high risk of future exacerbations and has been shown to reduce inflammatory cells and mediators in induced sputum, a surrogate of airway inflammation. However, these anti-inflammatory effects are yet to be confirmed in another robust study directly assessing inflammatory markers in bronchial sub-mucosa.
- FDA: Celgene's Otezla OK for Psoriatic Arthritis
I'm posting this article from MedPage Today not only for psoriasis sufferers but PDE-4's are also approved for treatment of COPD (see article above). This one has shown to have less GI side-effects than Rofumilast. PDE-4's are also showing promise as a potentially safer alternative to current treatments for a multitude of autoimmune conditions and some research suggests that they might even be beneficial for PH. It's a drug to keep an eye on.
- Helen P
- April 4, 2014
- Sanford Health Launches New Pulmonary Hypertension Clinic Service (Sioux Falls, SD)
Sanford Heart Hospital and Sanford Pulmonary Medicine Clinic are working together to launch Sanford Pulmonary Hypertension Clinic.
Sanford Pulmonary Hypertension Clinic is the first of its kind in South Dakota. The primary goal of this new clinic is to use the combined expertise of the medical team to extend the length and quality of life for pulmonary hypertension patients.
This new service focuses on a multidisciplinary approach consisting of a pulmonologist, a cardiologist, specially trained nurses, respiratory therapists and pharmacists. Sanford Heart cardiologist, Dr. Orvar Jonsson and Sanford Health pulmonologist, Dr. John Yu will lead the members of this multidisciplinary team and review each patient’s individual case to create a specific care plan for each unique case.
- April 3, 2014
- Pulmonary Hypertension Therapies Could Improve, Thanks To New Yale Study
While there is still much to be learned about this rare and deadly disease, a new study published researchers at Yale School of Medicine on pulmonary hypertension has revealed valuable insights into cells and how they function in relation to the onset and progression of the disease.
The new study, which was published in the February 27th edition of Cell Reports, highlights the researchers’ efforts to learn more about the specific cellular mechanisms that occur behind the scenes in terms of the way that cells are organized in pulmonary arteries in patients who have pulmonary hypertension. It is this organization of cells that has been found to directly lead to patients being short of breath and fatigued
”For the first time, we understand which cells are responsible and the cellular processes underlying their recruitment,” and adding that, “We looked at the mechanism involved in how these cells migrate along blood vessels.”
The result of diseases such as pulmonary hypertension and other vascular disorders such as atherosclerosis is the development of excess smooth muscle accumulation in vascular structures in the lungs. Healthy lungs have patterns that are similar is design to that of tree branches, and the smallest blood vessels that branch out from these structures normally do not have a muscular coating. In the case of PH, however,even these small blood vessel branches become muscularized, which in turn leads to labored breathing.
- Guidelines Developed for Pulmonary HTN in Sickle Cell Dz
Evidence-based guidelines have been developed for adult patients with sickle cell disease (SCD) and pulmonary hypertension. The guidelines have been published in the March 15 issue of the American Journal of Respiratory and Critical Care Medicine.
Elizabeth S. Klings, MD, from Boston University, and colleagues produced evidence-based recommendations relating to management of adult patients with pulmonary hypertension in SCD.
- April 2, 2014
- Pulmokine Awarded $1.5 Million Stage B VITA Contract to Advance Inhaled Kinase Inhibitors for Pulmonary Arterial Hypertension
Pulmokine announced it has been awarded a Stage B Vascular Interventions and Therapeutic Advances (VITA) contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund the performance of studies that will support an Investigational New Drug (IND) application to be submitted to the FDA. - See more at: http://www.globenewswire.com/news-release/2014/03/27/621975/10074308/en/Pulmokine-Awarded-1-5-Million-Stage-B-VITA-Contract-to-Advance-Inhaled-Kinase-Inhibitors-for-Pulmonary-Arterial-Hypertension.html#sthash.xIWUo0aX.dpuf
"Preclinical results of our novel, inhaled PDGF receptor inhibitor are quite compelling, showing a meaningful decrease in pulmonary pressures in animal models of PAH. Importantly, by interfering with the PDGF receptor pathway, our candidates have the potential to address an underlying cause of PAH, not merely to alleviate its symptoms," said Dr. Zisman, the CEO of Pulmokine. "The VITA contract will allow us to complete additional studies required to advance our lead candidate into Phase 1 clinical trials in patients with PAH." - See more at: http://www.globenewswire.com/news-release/2014/03/27/621975/10074308/en/Pulmokine-Awarded-1-5-Million-Stage-B-VITA-Contract-to-Advance-Inhaled-Kinase-Inhibitors-for-Pulmonary-Arterial-Hypertension.html#sthash.xIWUo0aX.dpuf
- April 1, 2014
- Pulmonary arterial hypertension common among Sjogrens Syndrome patients
Sjögren’s Syndrome is a chronic condition of the immune system that causes mucous membranes and moisture-secreting glands to function improperly. Dry eyes and mouth are the most common symptoms of the condition but in some cases the disease can affect major organ function.
A recent study found that pulmonary arterial hypertension (high blood pressure in the arteries in the lungs) is more common among patients with Primary Sjögren’s Syndrome.
The researchers discovered that the patients with pulmonary arterial hypertension were female, younger and had had Primary Sjögren’s Syndrome for a shorter amount of time.
Read more: http://www.dailyrx.com/pulmonary-arterial-hypertension-common-among-sjogrens-syndrome-patients#ixzz2xhEnaNPj
- Patients with Severe Pulmonary Hypertension Benefit from TAVR Despite Increased Mortality
the presence of pulmonary hypertension increases all-cause mortality at 1 year after transcatheter aortic valve replacement (TAVR), even patients with the most severe form of the condition reap functional benefits that render the therapy a reasonable option, according to a registry study published online February 25, 2014, ahead of print in Circulation: Cardiovascular Interventions.
- March 31, 2014
- Adempas (Riociguat) wins EU-Approval for PAH und CTEPH
BERLIN, Germany I March 31, 2014 I Bayer today announced that Adempas® (riociguat) has been approved by the European Commission for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Adempas is indicated for the treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and for the treatment of adult patients with pulmonary arterial hypertension (PAH) as a monotherapy or in combination with endothelin receptor antagonists. Adempas is a soluble guanylate cyclase (sGC) stimulator, and the first member of a novel class of compounds. Adempas is the first and only drug treatment approved for patients with CTEPH...
- FDA Clarifies Its Position on Revatio Use in Children
The FDA announced clarifications to its previous recommendation related to prescribing Revatio (sildenafil; Pfizer) for children with pulmonary arterial hypertension (PAH).
In August 2012, the Revatio drug label was revised with an added warning that stated “use of Revatio, particularly of chronic use, is not recommended in children.” This recommendation was based on data from a long-term clinical trial in pediatric patients that showed increasing mortality with increasing Revatio doses.
Although Revatio is approved only to treat PAH in adults, healthcare providers must consider whether the benefits of treatment are likely to outweigh the risks for each patient. The Agency noted that there may be circumstances in which the benefit-risk profile of Revatio may be acceptable in individual children, if other treatment options are limited.
The recommendation from August 2012 was not intended to suggest that Revatio should never be prescribed for pediatric use.
- March 30, 2014
- Bosentan Comes up Empty in Postmarket PAH Trial
Bosentan (Tracleer, Actelion), a Food and Drug Administration (FDA)–approved drug for pulmonary arterial hypertension (PAH), failed to reduce time to first morbidity or mortality compared with placebo treatment in the postmarket COMPASS 2 trial, the sponsor, Actelion, announced on March 17, 2014.
- Age-Adjusted D-dimer Cutoff to Rule Out PE Ready for Prime Time
The research team that developed an age-adjusted D-dimer cutoff level to rule out pulmonary embolism (PE) in the emergency department has validated it in a prospective study and thinks it's time to start using it.
- March 29, 2014
- IPAH cured in a single case?
"To the best of our knowledge, this is the first report of successful treatment of idiopathic pulmonary arterial hypertension, probably as a result of low-dose radiation to the pulmonary arterial main stems. The patient continues to have no specific complaints concerning her idiopathic pulmonary arterial hypertension."
This is the final statement of a case report, where a woman received a comparably low dose radiation treatment and the PVR (alias PAR) went down from more than 1300 to 400 dyn*s*cm-5 within 7 1/2 months after the mentioned radiation threatment, which deleted pulmonary arterial nerves and rose VIP level.
Click headline to find the abstract and then click the downlord button to get a full text PDF-download.
- 'Bendopnea': A New Symptom to Help Spot Sicker HF Patients?
Cardiologists in Texas have identified a new symptom to look for in patients with advanced heart failure—"bendopnea," which they define as "shortness of breath when bending forward."
- PCORI’s Research Will Answer Patients’ Real-World Questions
(Health Affairs Blog)
Established by Congress through the Patient Protection and Affordable Care Act as an independent research institute, PCORI is designed to answer real-world questions about what works best for patients based on their particular circumstances and concerns.
- March 27, 2014
- Sleep apnea: What you need to know
Each year the lives of millions of Americans are affected by sleep-related disorders, including obstructive sleep apnea (OSA). Sleep apnea is characterized by periods of partial or complete cessation of air flow during sleep. OSA has significant effect on health, safety and quality of life.
Sleep apnea is increasing among men and women. Recent data showed that among adults 30 to 70 years of age, 13 percent of men and 6 percent of women have moderate to severe sleep apnea. Unfortunately, as many as 85 percent of people who have sleep apnea remain undiagnosed and untreated...
- Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
It is now widely accepted that altered immune mechanisms play a significant role in PAH by recruiting inflammatory cells, remodeling the pulmonary vasculature, and promoting autoimmune responses.2–4 Inflammation is a general term for the local accumulation of fluid, plasma proteins, and white blood cells that is initiated by physical injury, infection, or a local immune response. These phenomena represent the innate immune …
- March 26, 2014
- New guidelines for sickle cell disease and PAH
THURSDAY, March 20, 2014 (HealthDay News) -- Evidence-based guidelines have been developed for adult patients with sickle cell disease (SCD) and pulmonary hypertension. The guidelines have been published in the March 15 issue of the American Journal of Respiratory and Critical Care Medicine.
Elizabeth S. Klings, M.D., from Boston University, and colleagues produced evidence-based recommendations relating to management of adult patients with pulmonary hypertension in SCD.
According to the report, decision making should be guided by stratification of mortality risk. For patient..
- United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment
United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin® (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost™ by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with United Therapeutics...
- Bayer initiates trial to assess riociguat for resistant pulmonary arterial hypertension
Bayer HealthCare announced enrollment of the first participant in the phase 3b RESPITE study.
The open-label, multicenter, international pilot study will assess the soluble guanylate cyclase stimulator riociguat (Adempas) in patients with pulmonary arterial hypertension who are resistant to treatment with phosphodiesterase-5 (PDE5) inhibitors, according to a press release.
The trial will include approximately 60 patients with PAH who received at least 3 months of prior treatment with sildenafil (Viagra/Revatio, Pfizer) or tadalafil (Cialis, Lilly) and did not demonstrate sufficient clinical responsiveness to PDE5 inhibitor treatment. Participants will receive 24 weeks of riociguat..